Dupixent, a drug cleared for eczema and many other autoimmune conditions, is one of the world’s best-selling medicines. But it doesn’t work for everyone, requires frequent injections and acts slowly, leaving opportunities for superior alternatives.
The race to one-up Dupixent has become one of the more competitive research pushes in the biopharmaceutical sector, with companies large and small advancing new options that might address the drug’s weaknesses. The prize is a piece of a market estimated to reach $37.3 billion by 2033, according to data analytics firm Grand View Research.
One of those entrants is Alameda, California-based Infinimmune, which on Tuesday announced that it raised $75 million in Series A venture funding to back its first two clinical prospects for the skin condition.
“The field is clinically crowded in atopic dermatitis, but is not commercially crowded,” CEO Wyatt McDonnell told BioPharma Dive. "From a mechanism perspective, the same thing is true. The existing systemic biologics treat a very specific inflammatory pathway.”
Wyatt McDonnell, a former 10xGenomics employee, is the co-founder and CEO of Infinimmune.
